Literature DB >> 16474422

The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model.

Antonio Ramón Martín1, Isabel Villegas, Marina Sánchez-Hidalgo, Catalina Alarcón de la Lastra.   

Abstract

Neutrophil infiltration, proinflammatory cytokines, eicosanoid generation and oxidative stress have been implicated in colitis. Resveratrol is a polyphenolic compound found in grapes and wine, with multiple pharmacological actions, including anti-inflammatory, antioxidant, antitumour and immunomodulatory activities. In a previous report, we documented that resveratrol decreases the degree of inflammation associated with acute experimental colonic inflammation, but its effects on chronic experimental colitis remain undetermined. The aim of this research was to investigate the effects of resveratrol on the chronic colonic injury caused by intracolonic instillation of trinitrobenzenesulphonic acid (TNBS) in rats. The inflammatory response was assessed by histology and myeloperoxidase activity. Tumour necrosis factor alpha (TNF-alpha) production, histological and histochemical analysis of the lesions were also carried out. We determined the production of prostaglandin (PG) E2 and D2 in colon mucosa, as well as cyclooxygenase (COX)-1 and -2 and nuclear transcription factor NF-kappa B (NF-kappaB) p65 protein expression. Finally, since resveratrol has been found to modulate apoptosis, we intended to elucidate its effects on colonic mucosa under chronic inflammatory conditions. Resveratrol (10 mg kg(-1) day(-1)) significantly attenuated the damage score and corrected the disturbances in morphology associated to injury. In addition, the degree of neutrophil infiltration and the levels of TNF-alpha were significantly ameliorated. Resveratrol did not modify PGD2 levels but returned the decreased PGE2 values to basal levels and also reduced COX-2 and the NF-kappaB p65 protein expression. Furthermore, treatment of rats with resveratrol caused a significant increase of TNBS-induced apoptosis in colonic cells. In conclusion, resveratrol reduces the damage in chronic experimentally induced colitis, alleviates the oxidative events, returns PGE2 production to basal levels and stimulates apoptosis in colonic cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474422      PMCID: PMC1760707          DOI: 10.1038/sj.bjp.0706469

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Colon epithelial cell death in 2,4,6-trinitrobenzenesulfonic acid-induced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production.

Authors:  G Yue; P S Lai; K Yin; F F Sun; R G Nagele; X Liu; K K Linask; C Wang; K T Lin; P Y Wong
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

2.  Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B.

Authors:  S W Chung; B Y Kang; S H Kim; Y K Pak; D Cho; G Trinchieri; T S Kim
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

3.  Experimental colitis induced by trinitrobenzenesulfonic acid: an ultrastructural and histochemical study.

Authors:  M I Torres; M García-Martin; M I Fernández; N Nieto; A Gil; A Ríos
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 4.  Etiology and pathogenesis of inflammatory bowel disease.

Authors:  C Schmidt; A Stallmach
Journal:  Minerva Gastroenterol Dietol       Date:  2005-06

5.  Assessment of leukocyte involvement during ischemia and reperfusion of intestine.

Authors:  M B Grisham; J N Benoit; D N Granger
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

6.  Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?

Authors:  Moammir Hasan Aziz; Shannon Reagan-Shaw; Jianqiang Wu; B Jack Longley; Nihal Ahmad
Journal:  FASEB J       Date:  2005-04-18       Impact factor: 5.191

7.  Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis.

Authors:  M N Ajuebor; A Singh; J L Wallace
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-07       Impact factor: 4.052

8.  Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase.

Authors:  M Holmes-McNary; A S Baldwin
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

9.  Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes.

Authors:  L M Hung; J K Chen; S S Huang; R S Lee; M J Su
Journal:  Cardiovasc Res       Date:  2000-08-18       Impact factor: 10.787

10.  Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production.

Authors:  X Gao; Y X Xu; N Janakiraman; R A Chapman; S C Gautam
Journal:  Biochem Pharmacol       Date:  2001-11-01       Impact factor: 5.858

View more
  60 in total

1.  Resveratrol suppresses colitis and colon cancer associated with colitis.

Authors:  Xiangli Cui; Yu Jin; Anne B Hofseth; Edsel Pena; Joshua Habiger; Alexander Chumanevich; Deepak Poudyal; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh; Lorne J Hofseth
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

Review 2.  Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis.

Authors:  Haim Shapiro; Pierre Singer; Zamir Halpern; Rafael Bruck
Journal:  Gut       Date:  2006-08-24       Impact factor: 23.059

Review 3.  Resveratrol and the eye: activity and molecular mechanisms.

Authors:  Christina Bola; Hannah Bartlett; Frank Eperjesi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-21       Impact factor: 3.117

4.  Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut.

Authors:  R Caruso; I Marafini; E Franzè; C Stolfi; F Zorzi; I Monteleone; F Caprioli; A Colantoni; M Sarra; S Sedda; L Biancone; P Sileri; G S Sica; T T MacDonald; F Pallone; G Monteleone
Journal:  Mucosal Immunol       Date:  2014-05-21       Impact factor: 7.313

5.  Effects of ferrofluid and phytoalexin spirobrassinin on thioflavin-T-based fluorescence in cerebrospinal fluid of the elderly and multiple sclerosis patients.

Authors:  Zdena Kristofikova; Zuzana Gazova; Katarina Siposova; Ales Bartos; Jan Ricny; Jolana Kotoucova; Jana Sirova; Daniela Ripova
Journal:  Neurochem Res       Date:  2014-05-25       Impact factor: 3.996

6.  Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells.

Authors:  Haider Rasheed Alrafas; Philip B Busbee; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Leukoc Biol       Date:  2019-03-21       Impact factor: 4.962

7.  Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis.

Authors:  Jan Seibel; Almut F Molzberger; Torsten Hertrampf; Ute Laudenbach-Leschowski; Patrick Diel
Journal:  Eur J Nutr       Date:  2009-02-21       Impact factor: 5.614

8.  Resveratrol inhibits prostaglandin formation in IL-1beta-stimulated SK-N-SH neuronal cells.

Authors:  Lena Wendeburg; Antonio Carlos Pinheiro de Oliveira; Harsharan S Bhatia; Eduardo Candelario-Jalil; Bernd L Fiebich
Journal:  J Neuroinflammation       Date:  2009-09-14       Impact factor: 8.322

Review 9.  Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety.

Authors:  Peter Kovacic; Ratnasamy Somanathan
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

Review 10.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.